Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

Sha_B_Ral Mar. 21 at 10:39 AM

$IOBT Taken from Reddit. Steve Cohen purchased 5.6% of the company's stock, and Jori Chinnett increased his holdings by 30%, now owning over 6.3% of the company's shares. Institutional investors and insiders combined hold 65–70% of the company's stock, and if stop-loss orders from last week and over-the-counter trading from last Friday are included, their ownership could reach 70–80%. While this is a massive scale, funds are running dry, so it appears the sale must be completed before March 31, preferably within this week.

1 · Reply

stevenryl86 Mar. 20 at 1:03 AM

$IOBT the ppl that short this, still lurking in here?? Holding until news out!

0 · Reply

GTMStox Mar. 19 at 7:49 PM

$IOBT a close over .19 would be nice, but I'll settle for a higher close than yesterday as well.😀

0 · Reply

GTMStox Mar. 19 at 3:21 PM

$IOBT "Higher highs and higher lows" on the daily is the name of the game here. Hopefully patience and pain endured will be rewarded.

1 · Reply

BadyBady Mar. 19 at 11:52 AM

$IOBT I expect the announcement of the news in the first half of 2026, possibly even the first quarter, because the current liquidity is only sufficient until the first half of this year.

1 · Reply

BadyBady Mar. 19 at 11:49 AM

$IOBT For me I will take the Risk😎, I expect any PR will fly . +150%

0 · Reply

BadyBady Mar. 19 at 11:46 AM

$IOBT Their operations are successful in many similar cases → In the distressed biotech sector, they succeed in asset sales or out-licensing more often than they completely fail. Their reputation in this field is strong (especially compared to some smaller advisors who leave companies to collapse without any deal)

0 · Reply

BadyBady Mar. 19 at 11:43 AM

$IOBT Raymond James, will not accept to engage as an advisor for IO Biotech (IOBT) unless it sees a realistic ability to reach a positive outcome. It will not accept just collecting fees while damaging its reputation by failing to deliver an excellent result for the company. In the end, this advisor has a strong track record and wants to maintain and even strengthen it. Thank you.

0 · Reply

GTMStox Mar. 18 at 7:55 PM

$IOBT a close over .18 would be nice, but I'll settle for a higher close than yesterday as well.

0 · Reply

GTMStox Mar. 18 at 6:47 PM

$IOBT There it goes...the daily shakeout..Absolute jokers

0 · Reply

IO Biotech Provides Corporate Update

Jan 21, 2026, 5:30 AM EST - 2 months ago

IO Biotech Announces Exploration of Strategic Alternatives

Dec 15, 2025, 4:05 PM EST - 3 months ago

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Nov 26, 2025, 10:46 AM EST - 4 months ago

IO Biotech Announces Participation in Upcoming December Investor Conferences

Nov 14, 2025, 8:05 AM EST - 4 months ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 12, 2025, 8:30 AM EST - 4 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 7, 2025, 9:00 AM EST - 4 months ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 20, 2025, 2:30 AM EDT - 5 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Sep 29, 2025, 7:05 AM EDT - 6 months ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 23, 2025, 8:05 AM EDT - 6 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Aug 14, 2025, 4:05 PM EDT - 7 months ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 11, 2025, 8:24 AM EDT - 7 months ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:00 AM EDT - 7 months ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 10, 2025, 8:00 AM EDT - 7 months ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

May 20, 2025, 8:05 AM EDT - 10 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 11 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 11 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 11 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 1 year ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 1 year ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 1 year ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 1 year ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 1 year ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 1 year ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 1 year ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 1 year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 1 year ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 7, 2024, 10:00 AM EST - 1 year ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 2 years ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 2 years ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 2 years ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 2 years ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 2 years ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 2 years ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Dec 21, 2023, 8:30 AM EST - 2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 23, 2023, 1:00 AM EDT - 2 years ago

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Oct 3, 2023, 4:30 PM EDT - 2 years ago

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 12, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Sha_B_Ral Mar. 21 at 10:39 AM

1 · Reply

stevenryl86 Mar. 20 at 1:03 AM

$IOBT the ppl that short this, still lurking in here?? Holding until news out!

0 · Reply

GTMStox Mar. 19 at 7:49 PM

$IOBT a close over .19 would be nice, but I'll settle for a higher close than yesterday as well.😀

0 · Reply

GTMStox Mar. 19 at 3:21 PM

$IOBT "Higher highs and higher lows" on the daily is the name of the game here. Hopefully patience and pain endured will be rewarded.

1 · Reply

BadyBady Mar. 19 at 11:52 AM

$IOBT I expect the announcement of the news in the first half of 2026, possibly even the first quarter, because the current liquidity is only sufficient until the first half of this year.

1 · Reply

BadyBady Mar. 19 at 11:49 AM

$IOBT For me I will take the Risk😎, I expect any PR will fly . +150%

0 · Reply

BadyBady Mar. 19 at 11:46 AM

0 · Reply

BadyBady Mar. 19 at 11:43 AM

0 · Reply

GTMStox Mar. 18 at 7:55 PM

$IOBT a close over .18 would be nice, but I'll settle for a higher close than yesterday as well.

0 · Reply

GTMStox Mar. 18 at 6:47 PM

$IOBT There it goes...the daily shakeout..Absolute jokers

0 · Reply

Nvidioso Mar. 18 at 11:49 AM

$IOBT the OS could be successfull however IOBT do not have enough time because it is out of money. So, the more successfull OS, the more time would be required. Now, after any action taken by the management, in terms of liquidity, we are facing a bankrupt or a buyout. For sure the buyout would have a huge discount due to the lack of suitable decisions made on time by the directors. Even there is a huge risk about using the great science with pacients who need it. A huge mistake from directors!

0 · Reply

GTMStox Mar. 18 at 10:53 AM

$IOBT Company is being priced for absolute failure but OS results could revive it.

0 · Reply

GTMStox Mar. 18 at 10:51 AM

$IOBT

0 · Reply

LordWorld Mar. 18 at 10:14 AM

$IOBT With preliminary data, those who are buying the dips are already aware, since, I repeat, with such a volume and the throwing out of shares, the price would have been 0 last week. After the announcement of the official IOBT figures, it will either take off into space 🚀 or... In the case of positive data, the stock will skyrocket, this will be the first stop, after which they will announce a merger and it will continue its flight.

0 · Reply

LordWorld Mar. 18 at 10:09 AM

$IOBT "Based on an intent-to-treat analysis, patients in the study treated with Cylembio in combination with pembrolizumab achieved 19.4 months of median progression free survival compared to 11.0 months in patients treated with pembrolizumab alone. Although not yet mature, a trend toward an improvement in overall survival was also observed [HR 0.79 (95% CI: 0.57-1.10)]; the company expects OS to mature over the next six to nine months." https://investors.iobiotech.com/news-events/news/news-details/2025/IO-Biotech-Announces-Clinical-Improvement-in-Progression-Free-Survival-Demonstrated-in-Pivotal-Phase-3-Trial-of-Cylembio-plus-KEYTRUDA-Pembrolizumab-for-the-Treatment-of-First-line-Advanced-Melanoma-but-Statistical-Significance-Narrowly-Missed/default.aspx#:~:text=Based%20on%20an%20intent%2Dto,next%20six%20to%20nine%20months. Everyone is waiting for the "Overall Survival" data, which should be released very soon, according to the press release.

0 · Reply

Sha_B_Ral Mar. 18 at 1:36 AM

$IOBT On Reddit... //////////////////////// Monday I think they made the last shake out by pushing the price down to 0.15 but there whales who’s buying the dip, they pushed the price up to 0.175 levels. Today shorts tried to push the price down TWICE but some “sneaky small investors” bought it right back heavly. That might be the last shake out. There are a lot of call options for $1 and strike for $2.5$ till friday, literally 5:1 call/put ratio. I’m expecting a buyout because reported data for institutions and insiders combined is %65-70 pct of the float Lundbeckfonden (%19.4) Vivo Capital (%12.8) Steve Cohen (%5.6) Mads Hald Andersen (%7.6) Jorey Chernett (%6.3) Passive Institutions (%18.3) So if they even wanted to sell anything THEY HAVE TO INFORM US WITH SEC FILLING!!! But they haven’t… I don’t think they will go bankrupcy, if you have some risk reward ratio, this is the stock for you.

1 · Reply

Sha_B_Ral Mar. 17 at 11:11 PM

$RZLV It must not surge yet. Absolutely not!!!!!! 🤣🤣🤣🤣🤣 My average is about $4. I haven’t been able to lower my average yet. Until I buy more, please wait just a little longer. 😁😁😁😁😁 The treasures I found. 💪VXRT (Mind-blowing technology — with the government and Sanofi behind it.) 👍RZLV 👌DVLT (Innovative technology — it will shake up the financial market.) 🫶SLS (Amazing efficacy — on the verge of an explosion.) $IOBT It seems acquisition news is finally coming. I wonder if anyone has overlapping stocks with me? Haha~ May everyone become wealthy in 2026. 💸💸💰💰🪙🪙

0 · Reply

TerryMolenaar Mar. 17 at 7:59 PM

$IOBT buy when everybody is

0 · Reply

VinnyLaw Mar. 17 at 7:57 PM

$IOBT The fact is that until there’s support, this will keep falling. There’s no buying pressure to keep this afloat. Also, I’m wondering if even Cohen dumped his shares. There’s no reason for a dump unless it’s known that there will be no return on any investment after a sale of assets. I’m becoming very bearish about this situation. It’s sad because it has been mismanaged.

0 · Reply

GTMStox Mar. 17 at 7:52 PM

$IOBT wow this is definitely in the POS category at this point

0 · Reply

LordWorld Mar. 17 at 7:49 PM

$IOBT More than 140,000 shares purchased in 1 second

1 · Reply

GTMStox Mar. 17 at 6:02 PM

$IOBT After 7 red days, I don't mind a little green but this could also dump befoe EOD.

0 · Reply

Market Cap	12.71M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	18.31

Volume	998,300
Avg Vol	12,207,518
Day's Range	N/A - N/A
Shares Out	71.95M
Stochastic %K	22%
Beta	0.43
Analysts	Sell
Price Target	$1.62